Visual Abstract: Efficacy of Pegasparaginase-Based Chemotherapy Regimen vs L-asparaginase–Based Regimen for Extranodal Natural Killer/T-Cell Lymphoma

JAMA Oncology

EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, JUNE 16, 2022

Media advisory: The full study and editorial are linked to this news release. A visual abstract is below.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2022.1968?guestAccessKey=e677efdb-e05c-46f6-9c45-8250fba74408&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061622

 

Visual Abstract

Authors: Mingzhi Zhang, M.D., of the First Affiliated Hospital of Zhengzhou University in Zhengzhou, China, is the corresponding author.

(doi:10.1001/jamaoncol.2022.1968)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.